Possibilities of dapagliflozin-induced cardioprotection on doxorubicin + cyclophosphamide mode of chemotherapy-induced cardiomyopathy
Ashot Avagimyan, Mohammad Sheibani, Nana Pogosova, Lusine Mkrtchyan, Hasmik Yeranosyan, Anahit Aznauryan, Karmen Sahaakyan, Federica Fogacci, Arrigo F.G. Cicero, Davood Shafie, Nizal Sarrafzadegan
Topics & Concepts
MedicineCardiotoxicityCyclophosphamideCardioprotectionDapagliflozinDoxorubicinCardiomyopathyEndothelial dysfunctionPharmacologyChemotherapyInternal medicineHeart failureLipid metabolismAngiogenesisCardiologyEndocrinologyDiabetes mellitusIschemiaType 2 diabetesChemotherapy-induced cardiotoxicity and mitigationCancer, Lipids, and MetabolismCardiovascular Function and Risk Factors